Yubo International Biotech (Yubo International Biotech) Debt-to-Equity : -0.14 (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Yubo International Biotech Debt-to-Equity?

Yubo International Biotech's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.20 Mil. Yubo International Biotech's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.09 Mil. Yubo International Biotech's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $-2.07 Mil. Yubo International Biotech's debt to equity for the quarter that ended in Mar. 2024 was -0.14.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Yubo International Biotech's Debt-to-Equity or its related term are showing as below:

YBGJ' s Debt-to-Equity Range Over the Past 10 Years
Min: -20.57 Med: -0.47 Max: 10.55
Current: -0.14

During the past 4 years, the highest Debt-to-Equity Ratio of Yubo International Biotech was 10.55. The lowest was -20.57. And the median was -0.47.

YBGJ's Debt-to-Equity is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 0.215 vs YBGJ: -0.14

Yubo International Biotech Debt-to-Equity Historical Data

The historical data trend for Yubo International Biotech's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Yubo International Biotech Debt-to-Equity Chart

Yubo International Biotech Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

0.27

-20.57

-1.40

-0.21

Yubo International Biotech Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial												-0.80	-0.49	-0.45	-0.21	-0.14

Competitive Comparison of Yubo International Biotech's Debt-to-Equity

For the Medical Instruments & Supplies subindustry, Yubo International Biotech's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Yubo International Biotech's Debt-to-Equity Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Yubo International Biotech's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Yubo International Biotech's Debt-to-Equity falls into.

Yubo International Biotech Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Yubo International Biotech's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.276	+	0.116)	/	-1.844
	=	-0.21

Yubo International Biotech's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.2	+	0.091)	/	-2.066
	=	-0.14

Yubo International Biotech (OTCPK:YBGJ) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Yubo International Biotech Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Yubo International Biotech's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Yubo International Biotech (Yubo International Biotech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Yubo International Biotech Ltd (OTCPK:YBGJ) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

31 Xishiku Avenue, Room 105, Building 5, Xicheng District, Beijing, CHN, 100034

Website

http://www.yubogroup.com

Yubo International Biotech Ltd is a technology company focused on the research and development and application of endometrial stem cells. It offers products and services under the brand VIVCELL. Its product offerings include healthcare products for the respiratory system, skincare products, hair care products, healthy beverages, and male and female personal care products. It also offers stem cell-related services including cell testing and health management consulting services. The company derives its revenue from the sale of nebulizers containing frozen tubes with medical fluid and from the sale of oral liquids health products. The nebulizers are sold directly to consumers on its online e-commerce platform.

Executives

Lina Liu	10 percent owner, officer: CFO, Treasurer and Secretary	MAGNA-LAB, INC., ROOM 105, BUILDING 5, 31 XISHIKU AVENUE, XICHENG DISTRICT, BEIJING F4 00000
Focus Draw Group Ltd	10 percent owner	C/O YUBO INTERNATIONAL BIOTECH LIMITED, ROOM 105, BUILDING 5, 31 XISHIKU AVENUE, XICHENG DISTRICT, BEIJING F4 00000
Boao Biotech Ltd	10 percent owner	C/O YUBO INTERNATIONAL BIOTECH LIMITED, ROOM 105, BUILDING 5, 31 XISHIKU AVENUE, XICHENG DISTRICT, BEIJING F4 00000
Flydragon International Ltd	10 percent owner	C/O YUBO INTERNATIONAL BIOTECH LIMITED, ROOM 105, BUILDING 5, 31 XISHIKU AVENUE, XICHENG DISTRICT, BEIJING F4 00000
Chinaone Technology Ltd	10 percent owner	C/O YUBO INTERNATIONAL BIOTECH LIMITED, ROOM 105, BUILDING 5, 31 XISHIKU AVENUE, XICHENG DISTRICT, BEIJING F4 00000
Bai Zhihui	director	MAGNU-LAB, INC., ROOM 105, BUILDING 5, 31 XISHIKU AVENUE, XICHENG DISTRICT, BEIJING F4 00000
Wang Jun	director, officer: President and CEO	MAGNA-LAB, INC., ROOM 105, BUILDING 5, 31 XISHIKU AVENUE, XICHENG DISTRICT, BEIJING F4 00000
Wang Yang	director	MAGNA-LAB, INC., ROOM 105, BUILDING 5, 31 XISHIKU AVENUE, XICHENG DISTRICT, BEIJING F4 00000
Joel S Kanter	director	C/O APPLIED UV, INC., 150 N. MACQUESTEN PKWY, MOUNT VERNON NY 10550
Jonathan Adereth	director	C/O MEDIVISION, PO BOX 45 INDUSTRIAL PARK, YOKNEAM ISRAEL
Magna Acquisition Llc	10 percent owner	8000 TOWERS CRESCENT DRIVE, SUITE 1070, VIENNA VA 22182
Kenneth C Riscica	officer: Treasurer and Secretary	C/O MAGNA-LAB INC., 6800 JERICHO TURNPIKE, SUITE 120W, SYOSSET NY 11791
Lawrence A Minkoff	director, officer: Chairman, President, CSO	C/O MAGNA-LAB INC, 6800 JERICHO TURNPIKE, SUITE 120W, SYOSSET NY 11791
Jerome M Feldman	director	C/O MAGNA-LAB INC, 6800 JERICHO TURNPIKE SUITE 120W, SYOSSET NY 11791
Seymour Kessler	director	C/O MAGNA-LAB INC., 6800 JERICHO TURNPIKE #120W, SYOSSET NY 11791

Yubo International Biotech (Yubo International Biotech) Headlines

No Headlines